Compare AISP & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AISP | CNTX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.1M | 116.7M |
| IPO Year | N/A | 2021 |
| Metric | AISP | CNTX |
|---|---|---|
| Price | $3.14 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 828.4K | ★ 1.6M |
| Earning Date | 03-02-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,033,886.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $216.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.71 | $0.49 |
| 52 Week High | $7.20 | $2.00 |
| Indicator | AISP | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 65.96 |
| Support Level | $3.05 | $1.46 |
| Resistance Level | $3.34 | $1.79 |
| Average True Range (ATR) | 0.21 | 0.17 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 67.20 | 56.59 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.